Citing Supplier Problems, Janssen Says Another Doxil Shortage Is Coming

Persistent “difficulties” with a key supplier, Ben Venue Laboratories, are expected to result in another shortage of Janssen’s ovarian cancer drug Doxil sometime next month, the company warned. The Johnson & Johnson subsidiary “cannot estimate” when Doxil will be available again, the company said in a letter, which urges existing patients to instead use an FDA-approved generic of doxorubicin HCl liposome injection manufactured by India’s Sun Pharma.
Drug Industry Daily